

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Lee's Pharmaceutical Holdings Limited

李氏大藥廠控股有限公司*

(incorporated in the Cayman Islands with limited liability)

(Stock Code: 950)

VOLUNTARY ANNOUNCEMENT – UNIDROX® PRULIFLOXACIN TABLET OBTAINED IMPORTED DRUG LICENSE FROM CHINA'S NATIONAL MEDICAL PRODUCTS ADMINISTRATION

This announcement is made by the board (the “**Board**”) of directors (the “**Directors**”) of Lee's Pharmaceutical Holdings Limited (the “**Company**” or “**Lee's Pharm**”, together with its subsidiaries as the “**Group**”) on a voluntary basis.

The Board of the Company is pleased to announce that on 12 June 2020, Lee's Pharmaceutical (HK) Limited, a wholly-owned subsidiary of the Company, has successfully obtained the Imported Drug License for Unidrox® (Prulifloxacin tablet) from China's National Medical Products Administration for the treatment of patients with acute uncomplicated lower urinary tract infections (simple cystitis), complicated lower urinary tract infections, acute exacerbation of chronic bronchitis, or acute bacterial rhinosinusitis. Prulifloxacin is manufactured by the Italian company Angelini Pharma.

According to the Journal of Ethnopharmacology 241 (2019), the incidence rate of urinary tract infections accounted for 0.91% of the total population in China.

The prevalence rate of chronic bronchitis among people above 40 years old in China reaches up to 8.2%. Repeated acute exacerbation of chronic bronchitis reduces the life quality of patients, enhances pulmonary dysfunction, and increases the fatality rate, according to the Community Acquired Infection 2015.

Acute bacterial rhinosinusitis is more frequent in children than adults. It is estimated that 6–9% of viral common colds in children are complicated by bacterial rhinosinusitis while the rate is 0.5–2% for adults, according to Hong Kong Department of Health.

* For identification purpose only

ABOUT PRULIFLOXACIN

Prulifloxacin was discovered by Nippon Shinyaku Co., Ltd (“**Nippon Shinyaku**”) as an oral quinolone antibacterial agent, Prulifloxacin tablet has been launched in Japan since December 2002 and in Europe by Angelini Pharma, the manufacturer of the product, since October 2004. The Group entered into the license agreement with Nippon Shinyaku in 2009 for an exclusive marketing right of products containing Prulifloxacin in China.

ABOUT NIPPON SHINYAKU

Nippon Shinyaku Co., Ltd., a Japan-based company founded in 1919, is an R&D oriented pharmaceutical company. It specialises in the development, manufacture, and sale of ethical drugs for the treatment of orphan/intractable diseases, urological diseases, gynaecologic diseases, and haematologic malignancies. Its mission is to help people lead healthier and happier lives. Through creating unique medicines that will bring hope to patients and families struggling with illness, it aims to be an organisation trusted by the community. Nippon Shinyaku is headquartered in Kyoto, Japan.

ABOUT ANGELINI PHARMA

Angelini Pharma is the pharmaceutical division of Angelini Holding. Angelini Holding was founded in Italy at the beginning of the 20th century – almost 100 years ago – over the years it has grown into a leading international group in healthcare. Angelini Pharma today pledges in the fields of mental health (including pain), rare diseases and consumer, with highly successful over-the-counter (OTC) brands in Italy and abroad. Angelini Pharma is an integrated pharmaceutical company with extensive and well-recognised R&D programmes, in addition to world-class production facilities and international marketing activities of key compounds and leading drugs in many sectors. Strategic partnerships with international companies complete and expand the geographical areas where it operates. Angelini Pharma products are marketed in about 70 countries. It operates directly in 15 countries, employing more than 2,700 people and commercialises its products in more than 50 countries through strategic alliances with leading international pharmaceutical groups.

ABOUT LEE'S PHARM

Lee's Pharm is a research-driven and market-oriented biopharmaceutical company with more than 25 years of operation in the pharmaceutical industry in China. The Company is fully integrated with solid infrastructures in drug development, clinical development, regulatory, manufacturing, sales and marketing based in Mainland China with global perspectives. The Company has established extensive partnerships with over 20 international companies and currently markets 23 proprietary and licensed-in pharmaceutical products in Mainland China, Hong Kong, Macau and Taiwan. The Company focuses on several key disease areas such as cardiovascular, woman health, paediatrics, rare diseases, oncology, ophthalmology, dermatology, obstetrics and urology. It has more than 60 products under different development stages stemming from both internal research and development as well as from the licensing and development, commercialisation, and manufacturing rights from various United States, European and Japanese companies.

By order of the Board
Lee's Pharmaceutical Holdings Limited
Lee Siu Fong
Chairman

Hong Kong, 26 June 2020

As at the date of this announcement, Ms. Lee Siu Fong (Chairman), Ms. Leelalertsuphakun Wanee and Dr. Li Xiaoyi are executive Directors, Mr. Simon Miles Ball is a non-executive Director, Dr. Chan Yau Ching, Bob, Mr. Lam Yat Cheong and Dr. Tsim Wah Keung, Karl are independent non-executive Directors.